Get the Stockscreener App
4.42
3.91%
-0.18
Pre-market:
4.46
0.04
+0.90%
Precigen Inc stock is traded at $4.42, with a volume of 3.61M.
It is down -3.91% in the last 24 hours and up +13.33% over the past month.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
See More
Previous Close:
$4.60
Open:
$4.54
24h Volume:
3.61M
Relative Volume:
0.81
Market Cap:
$1.58B
Revenue:
$9.68M
Net Income/Loss:
$-250.64M
P/E Ratio:
-3.1576
EPS:
-1.3998
Net Cash Flow:
$-89.83M
1W Performance:
+4.99%
1M Performance:
+13.33%
6M Performance:
-8.87%
1Y Performance:
+237.40%
1-Day Range:
$4.36
$4.63
1-Week Range:
$4.02
$4.87
52-Week Range:
$1.28
$5.465
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
4.42 | 1.64B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Equities Analysts Set Expectations for Precigen Q3 Earnings - MarketBeat
Precigen’s lead cancer therapy is fueling a massive stock rally — here’s what Wall Street sees next - MSN
Precigen Q1 earnings preview - MSN
How Surging PAPZIMEOS Revenue And Narrower Losses At Precigen (PGEN) Have Changed Its Investment Story - simplywall.st
Earnings Beat: Precigen, Inc. (NASDAQ:PGEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Point72 (PGEN) reports 6.74M shares, 1.9% stake as of Mar 31, 2026 - Stock Titan
Precigen, Inc. (NASDAQ:PGEN) Q1 2026 Earnings Call Transcript - Insider Monkey
PGEN Stock Price, Quote & Chart | PRECIGEN INC (NASDAQ:PGEN) - ChartMill
Precigen (PGEN) Shares Surge After Strong Q1 2026 Earnings Repor - GuruFocus
Precigen (PGEN) Reports Strong Q1 Earnings, Shares Surge Nearly 18% - GuruFocus
Earnings call transcript: Precigen beats Q1 2026 forecasts, stock surges - Investing.com UK
Earnings call transcript: Precigen beats Q1 2026 forecasts, stock surges By Investing.com - Investing.com Australia
Precigen Earnings Call Highlights PAPZIMEOS Launch Surge - TipRanks
PGEN Maintained by Citizens -- Price Target Raised to $11.00 - GuruFocus
Precigen stock jumps after Q1 2026 beat (PGEN:NASDAQ) - Seeking Alpha
Precigen Stock Climbs After Strong 1Q for Papzimeos Sales - Moomoo
Precigen: Full Commercial Validation And Room To Run (NASDAQ:PGEN) - Seeking Alpha
Precigen (PGEN) Surges 27.6% in Premarket Trading - GuruFocus
This Biotech Has Soared Nearly 200% In A Year — Now Analysts See More Upside Ahead - Stocktwits
H.C. Wainwright raises Precigen stock price target on strong Papzimeos sales - Investing.com UK
Precigen, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors - TechStock²
Precigen price target raised to $11 from $10 at H.C. Wainwright - TipRanks
Citizens raises Precigen stock price target on strong launch By Investing.com - Investing.com Australia
Precigen price target raised to $11 from $9 at Citizens - TipRanks
Why is Precigen stock surging today? By Investing.com - Investing.com Canada
PGEN Rated Buy by HC Wainwright & Co. -- Price Target Raised to $11.00 - GuruFocus
Citizens raises Precigen stock price target on strong launch - Investing.com UK
Precigen Inc (PGEN) Q1 2026 Earnings Call Highlights: Strong Rev - GuruFocus
PGEN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Precigen (PGEN) Reports Strong Q1 2026 Revenue Growth - GuruFocus
Precigen Q1 Earnings Call Highlights - Inkl
PGEN Reports Strong Q1 Revenue and Positive Launch Performance - GuruFocus
Is Precigen (PGEN) 144.1% Overvalued After Q1 2026? GAAP EPS -$0 - GuruFocus
Earnings call transcript: Precigen Inc. Q1 2026 sees revenue surge By Investing.com - Investing.com India
Precigen reports Q1 EPS (2c) vs. (18c) last year - TipRanks
Precigen earnings beat, revenue topped estimates By Investing.com - Investing.com Canada
Precigen (PGEN) Q1 2026 Earnings Transcript - The Globe and Mail
PGEN: Q1 2026 revenue surged to $21.6M for PAPZIMEOS, with strong adoption and robust outlook - TradingView
Precigen Q1 Net Income USD -7.929 Million - TradingView
Transcript: Precigen Q1 2026 Earnings Conference Call - Benzinga
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):